Contraception

These are the top 5 headlines you might have missed from May 2026.

Mifepristone via mail order and telehealth may continue after a Supreme Court ruling kept access in place while a lawsuit progresses.

Daré Bioscience reported that 1789 menstrual cycles of data have been reviewed for Ovaprene, with the DSMB recommending that the trial proceed without modifications.

The Ringza slow-release vaginal ring has launched in Canada and is designed to be re-used for up to 1 year.

The extended approval and contracpetive efficacy during use from 3 to 5 years was based on a multicenter, single-arm, open-label study (NCT04626596) conducted in the United States.

Analysis of internal FDA records reveals that mifepristone’s REMS program was shaped by repeated evidence-based safety reviews.

Check out the 5 biggest contraception stories of 2025, and review best practices.

Explore the latest findings on copper IUDs, including new options and efficacy data, shaping the future of non-hormonal contraception.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

Researchers have observed a significant rise in tubal ligation rates following the June 2022 Dobbs decision.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

A study found widespread disparities in contraceptive access, adverse effect burdens, and limited male-focused options.

The FDA’s investigational device exemption approval allows FemBloc to enter the final phase of its pivotal trial.

Three-year results from the ACCORd trial show sustained LARC use, higher satisfaction, and fewer unintended pregnancies with physician training.

A study found early medical abortion at home up to 12 weeks’ gestation is as safe and effective as in-hospital care, supporting expanded access.

On October 2, 2025, the FDA approved a generic version of mifepristone to be used in a regimen with misoprostol for abortion.

Study finds immediate postpartum IUD placement increases long-term use but raises expulsion risk compared with delayed insertion.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

A new study reveals that hormonal contraceptives not only regulate reproductive health but also influence emotional reactivity.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

A study found that 11% of intrauterine device removals have complications, with higher rates among Spanish-speaking patients.

A new study finds higher rates of cyanotic congenital heart disease in states with abortion restrictions following the 2022 Supreme Court ruling.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

New research shows up to 17% of reproductive-aged women visit crisis pregnancy centers, raising alarms over misinformation and lack of regulation.